Top best Life Sciences & Biotechnology Lawyers in Washington | 117 available

Regulatory attorney with experience in both the legislative and executive branches, as well as with  national and international law firms.. Specialties: Food, drug, dietary supplement, tobacco, medical device, and healthcare regulation; regulatory compliance and enforcement; healthcare-related transactions; federal appropriations law; telecommunications law and policy; regulatory analysis; and congressional affairs.

Registered U.S. patent attorney with Ph.D. in microbiology specializing in biotechnology, pharmaceutical (small molecule and biologics) and medical device patent litigation and strategic counseling.

My practice focuses on mergers and acquisitions and equity and debt financing transactions, but I handle a wide array of commercial matters, including business combinations; distressed asset transactions; joint ventures; strategic alliances; various commercial and complex contracting arrangements, such as employment, consulting, service, supply, and distribution agreements; corporate governance issues; and other general corporate matters.

Ms. Ehrlich represents clients regulated by the US Food and Drug Administration, Federal Trade Commission, Consumer Product Safety Commission, Drug Enforcement Administration, Department of Agriculture, and other health and safety regulatory agencies at both the Federal and State level. While her practice includes all aspects of consumer product regulation, Ms. Ehrlich has particular expertise with the marketing and labeling of dietary supplements, cosmetics and conventional foods, pharmaceutical and medical device clearance and marketing, Lanham Act false advertising and administrative litigation, and privacy issues affecting pharmaceutical and medical device companies.  Ms. Ehrlich advises clients in a wide range of matters, including issues related to pharmacy compounding, non-patent exclusivity, and health care fraud and abuse.

I have over fourteen years of experience in intellectual property law beginning as a Patent Examiner examining biotechnology patent applications with a focus on molecular biology, microbiology, genetically engineered plants and plant genes in art unit 1638.  Post Patent Office experience has included preparing and prosecuting patent applications in a wide variety of technologies; patent portfolio management; patent portfolio analysis; merger and acquisition due diligence; managing due diligence projects; infringement and validity studies; freedom to operate studies; licensing; drafting material transfer and confidentiality agreements; preparing litigation strategies; managing litigation teams; drafting motions in both litigation and interference proceedings; drafting briefs in support of motions; deposition practice; discovery practice; legal research; training junior attorneys; and client relations and management responsibilities.  Further experience includes research assistant positions both in a cutting edge molecular genetics lab and a university affiliated environmental lab.

Christine P. Bump is an insightful regulatory attorney with 20 years of experience developing and implementing FDA and related regulatory strategies for cutting-edge technology. She focuses on issues relating to devices, diagnostics, genetics and genomics, digital health, wellness, and advertising and promotion. Christine has been working on laboratory developed test (LDT) issues since 2004. She counsels laboratories, academic medical centers, start-ups, and large corporations, and advises clients with an understanding of their business and strategic goals. Christine has prepared clinical trial and customer user agreements for laboratory and wellness products, with emphases on patient and data privacy.. She has also developed regulatory strategies for new technologies related to IVF and pre-implantation selection, and served as dedicated counsel to a fertility clinic. Christine's policy experience includes serving as a regulatory counsel for national coalition of diagnostic companies. She has prepared unified comments on behalf of a coalition to FDA and Congress, and prepared lobbyists for meetings on Capitol Hill regarding alternatives to existing and proposed regulations.